The valve may now be used to replace failing heart valves previously implanted in high risk patients, according to the report. Clinicians place the Sapein 3 valve into the failing valve through a blood vessel or small incision in the patient’s chest, which offers a less invasive treatment option than repeat open heart surgery.
The FDA originally approved the valve as a replacement for a patient’s natural valve when open heart surgery is deemed too risky.
More articles on supply chain:
Premier: 9 policy recommendations to fix high drug costs
6 FDA decisions to keep an eye on in June
Eli Lilly CFO to retire at year-end
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.